A5101050030- HER2/EGFR in Cancer Research
- Anesthesia and Pain Management
- Synthesis and biological activity
- Corneal surgery and disorders
- Cholinesterase and Neurodegenerative Diseases
- Monoclonal and Polyclonal Antibodies Research
- Thyroid and Parathyroid Surgery
- Cancer Immunotherapy and Biomarkers
- Nerve injury and regeneration
- Pancreatic and Hepatic Oncology Research
- Synthesis and Reactions of Organic Compounds
- Helicobacter pylori-related gastroenterology studies
- Immune cells in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Thermal Regulation in Medicine
- Sirtuins and Resveratrol in Medicine
- Computational Drug Discovery Methods
- Phagocytosis and Immune Regulation
- Airway Management and Intubation Techniques
- Cardiac, Anesthesia and Surgical Outcomes
- Bioactive Compounds and Antitumor Agents
- Spinal Cord Injury Research
Nanjing Medical University
2016-2024
Jiangsu Province Hospital
2016-2024
Second Affiliated Hospital of Zhejiang University
2024
Guangdong Provincial People's Hospital
2023
Fujian Medical University
2023
Guangdong Academy of Medical Sciences
2023
Southern Medical University
2023
Hunan Children's Hospital
2023
Gallbladder cancer (GBC) was once considered a contraindication for laparoscopic surgery, but it is becoming more common to use surgery GBC treatment. The aim of this study analyze the long- and short-term outcomes patients with advanced T-staged treated curative intent as defined by National Comprehensive Cancer Network (NCCN) after resection (LR) versus open (OR).
Abstract Background: BL-B01D1 is a first-in-class novel antibody drug conjugate (ADC) consisting of an EGFRxHER3 bispecific bounded to TOP-I inhibitor payload via cleavable linker. We now present safety/efficacy data from phase I study in breast cancer. Methods: This included patients (pts) with locally advanced or metastatic cancer (BC) and other solid tumors. was administered intravenously at doses 2.5mg/kg Day 1 & 8 every 3 weeks (D1D8Q3W) 5.0mg/kg (D1Q3W) during dose escalation...
Abstract Background: BL-M07D1 is an anti-HER2 antibody-drug conjugate (ADC) comprised of a humanized antibody, cathepsin B cleavable linker, and novel topoisomerase I inhibitor (Ed-04). Methods: This study included subjects with locally advanced or metastatic HER2 expressing (positive/low) breast cancer (BC) other solid tumors. would be administered at doses 1.0mg/kg Day 1 & 8 every 3 weeks (D1D8 Q3W) 2.6, 3.2, 3.8, 4.4, 5.0, 5.6, 6.2, 6.8 7.4 mg/kg (D1Q3W) during dose escalation...
Abstract With advancements in genomics and immunology, immunotherapy has emerged as a revolutionary strategy for tumor treatment. However, pancreatic ductal adenocarcinoma (PDAC), an immunologically “cold” tumor, exhibits limited responsiveness to immunotherapy. This study aimed address the urgent need uncover PDAC’s immune microenvironment heterogeneity identify molecular mechanisms driving evasion. Using single-cell RNA sequencing datasets spatial proteomics, we discovered LIM domain only...
Caudal anesthesia alleviates the strong pain endured by children during surgical treatment for concealed penis. In traditional method, anesthesiologists identify puncture point using 'blind probe' which leads to induction failure in children. Ultrasound has recently gained wide attention its guidance peripheral nerve block analgesia. However, clinical significance of wireless ultrasound - guided caudal technology remains unexplored. This study investigated value undergoing penis surgery....